Phaseline

Targets › UNKNOWN

UNKNOWN: drug programs, companies and trials

58 programs from 52 companies in 176 trials: 80 Phase 2, 35 Phase 4, 35 Phase 3, 26 Phase 1; Infectious disease, Oncology, Cardiovascular; next expected readout Nov 2026.

Open in Phaseline: the race on UNKNOWN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vanderbilt University Medical Center[18F]MH.MZ
Bacterial penicillin-binding protein inhibitor
HTR2A, UNKNOWN, BDKRB2, Ion channelsPhase 4Neurodegenerative Diseases; Osteoarthritis, Knee; Pain; Intradialytic Hypotension …Nov 2026
Brigham and Women's HospitalMIB 626 (NMN)
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2CPhase 4Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension …Nov 2026
Wroclaw Medical UniversityFerinject (FCM)
Intravenous ferric carboxymaltose for iron repletion
UNKNOWNPhase 4Myocardial Infarction, AcuteDec 2026
University of IowaMetronidazole 0.75% Topical Gel
Antibiotic/antimicrobial agent (topical)
UNKNOWNPhase 4HealthyDec 2026
University of AlbertaCiprofloxacin
Bacterial DNA gyrase inhibitor; Topoisomerase IV inhibitor
UNKNOWNPhase 4Idiopathic Overactive Bladder; Neurogenic BladderMar 2027
University of California, San Franciscon-acetylcysteine (NAC)
Mucolytic agent that breaks down disulfide bonds in mucoproteins
UNKNOWNPhase 4AsthmaApr 2027
National University of SingaporeCeftazidime
Bacterial penicillin-binding protein inhibitor
UNKNOWNPhase 4Blood Stream Infections; Bloodstream InfectionOct 2027
Monash UniversityCefazolin
Bacterial penicillin-binding protein inhibitor
UNKNOWNPhase 4Surgical Site InfectionDec 2027
Hospital de Clinicas de Porto AlegreCefuroxime Axetil
Bacterial penicillin-binding protein inhibitor
UNKNOWNPhase 4Pyelonephritis in PregnancyDec 2027
Assistance Publique - Hôpitaux de ParisAmikacin
Aminoglycoside antibiotic; inhibits bacterial protein synthesis by binding to 30S ribosoma
UNKNOWNPhase 4Pyelonephritis Acute; Pneumonia, BacterialJan 2028
Assistance Publique - Hôpitaux de ParisCefixime
Bacterial penicillin-binding protein inhibitor
UNKNOWNPhase 4Pyelonephritis AcuteJan 2028
Assistance Publique - Hôpitaux de ParisCotrimoxazole (sulfamethoxazole/trimethoprime)
Fixed-dose combination of sulfonamide and dihydrofolate reductase inhibitor; inhibits bact
UNKNOWNPhase 4Pyelonephritis AcuteJan 2028
Theis S. ItenovN-Acetylcysteine
Antioxidant and glutathione precursor
UNKNOWNPhase 4SepsisFeb 2028
Cairo UniversityAcetyl cysteine
Mucolytic agent that reduces mucus viscosity
UNKNOWNPhase 4Ventilation Acquired PneumoniaMar 2028
University of Newcastle, AustraliaRifampin
Bacterial DNA-directed RNA polymerase inhibitor
UNKNOWNPhase 4Prosthetic Joint Infections of HipDec 2029
University Hospital, ToursCefazolin
Bacterial penicillin-binding protein inhibitor
UNKNOWNPhase 4Hemodialysis Catheter Infection–
St. Joseph's Hospital and Medical Center, PhoenixGentamicin
Bacterial 70S ribosome inhibitor
UNKNOWNPhase 4Catheter Infection–
The Aurum Institute NPCRifapentine
Bacterial DNA-directed RNA polymerase inhibitor
RIPA, INH, UNKNOWNPhase 4HIV Seropositivity–
Colgate PalmoliveColgate SNaP Total 10/10, 1.5 Taurate
Stannous fluoride toothpaste (0.454% SnF, 1100 ppm F) with taurate
UNKNOWNPhase 3Plaque, DentalNov 2026
Sun Yat-sen UniversityCCRT with cisplatin
DNA cross-linking alkylating agent
UNKNOWNPhase 3Nasopharyngeal Carcinoma; Squamous Cell Carcinoma of Head and Neck; SBRT; Laryngeal Cancer …Dec 2026
Mt. Sinai Medical Center, MiamiEdetate Disodium
Chelation therapy for removal of environmentally acquired toxic metals
UNKNOWNPhase 3Critical Limb IschemiaDec 2026
Wake Forest University Health SciencesMagnesium Sulfate 2 G
Electrolyte supplementation; antiarrhythmic mechanism likely via effects on cardiac conduc
UNKNOWNPhase 3Tachycardia Atrial; MigraineDec 2026
Suleyman Demirel UniversityN-acetyl cysteine
Antioxidant; may reduce contrast-induced nephropathy and periprocedural myocardial injury
UNKNOWNPhase 3Coronary Artery Disease; Acute ST Segment Elevation Myocardial InfarctionDec 2026
Radboud University Medical CenterOptimised dose rifampicin (1800 mg)
Inhibition of bacterial RNA polymerase
UNKNOWNPhase 3Tuberculosis, PulmonaryDec 2026
Gilead SciencesLenacapavir
Structural capsid protein inhibitor
CA, CPSF6, GAG, PROT, UNKNOWN, CAPSIDPhase 3Pre-Exposure Prophylaxis of HIV Infection; HIV Pre-exposure Prophylaxis; HIV Infections; HIV-1-infection …Mar 2027
VaxcyteVAX-31 (low dose)
31 valent pneumococcal conjugate vaccine
UNKNOWNPhase 3Pneumococcal Disease; Pneumococcal VaccinesMar 2027
Medicines Development for Global HealthMoxDA
Antiparasitic combination: moxidectin + diethylcarbamazine + albendazole for lymphatic fil
UNKNOWNPhase 3Lymphatic FilariasisJun 2027
West China HospitalOxaliplatin
Third-generation platinum-based chemotherapy agent; forms DNA adducts and crosslinks
UNKNOWNPhase 3Rectal Cancer; Gastroesophageal Junction AdenocarcinomaDec 2027
Shanghai Jiao Tong University School of Medicinecyclophosphamide (reduced-dose PTCy)
Alkylating agent; post-transplantation cyclophosphamide causes selective alloreactive T-ce
UNKNOWNPhase 3Allogeneic Hematopoietic Cell TransplantDec 2027
Centre Hospitalier Universitaire de NiceRifampin
Bacterial DNA-directed RNA polymerase inhibitor
UNKNOWNPhase 3Infections Joint ProstheticMay 2028
University Hospital, ToursRabbit Anti thymocyte globulin (rATG)
Polyclonal lymphocyte-depleting antibody targeting T lymphocytes
UNKNOWNPhase 3Renal Transplant RejectionDec 2030
Huashan HospitalIsoniazid
Enoyl-[acyl-carrier-protein] reductase inhibitor
UNKNOWNPhase 3Tuberculosis–
Pirogov Russian National Research Medical UniversityMicronized purified flavonoid fraction (MPFF) 1000
Venotonic agent with angioprotective properties; reduces venous distensibility and blood s
UNKNOWNPhase 3Pelvic Venous Disorders–
Medicines Development for Global HealthMoxidectin
Antiparasitic agent targeting nematode neuromuscular function
UNKNOWNPhase 3Onchocerciasis–
The University of Texas Health Science Center at San AntonioLomustine
Nitrosourea alkylating agent
UNKNOWNPhase 2GlioblastomaNov 2026
Fudan UniversityVitamin C
Antioxidant, potential pro-oxidant at high doses
UNKNOWNPhase 2Pancreatic CancerNov 2026
Thomas Jefferson UniversityN acetyl cysteine (NAC)
Antioxidant; precursor for glutathione synthesis; may support dopaminergic function
UNKNOWNPhase 2Parkinson DiseaseJan 2027
Michael Bau MortensenOxaliplatin
DNA cross-linking agent delivered via pressurized intraperitoneal aerosol chemotherapy (PI
UNKNOWNPhase 2Peritoneum CancerMar 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineStupp regimen (oral temozolomide)
Oral alkylating agent
UNKNOWNPhase 2Glioblastoma (GBM)Apr 2027
The University of Hong KongPressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin
Pressurized intraperitoneal aerosol delivery of oxaliplatin
UNKNOWNPhase 2Peritoneal MetastasesAug 2027
Northern Jiangsu People's HospitalOxaliplatin
Third-generation platinum-based alkylating agent
UNKNOWNPhase 2Hepatocellular Carcinoma (HCC)Sep 2027
Tata Memorial CentreStandardized Withaferin-A (SWA)
Withaferin-A (standardized root extract of Withania somnifera)
UNKNOWNPhase 2Hematological MalignancyJan 2028
Vanderbilt University Medical CenterMetronidazole
Nitroimidazole antibiotic targeting anaerobic bacteria and protozoa
UNKNOWNPhase 2Acute Uncomplicated DiverticulitisApr 2028
ECOG-ACRIN Cancer Research GroupTemozolomide
Alkylating agent; methylates DNA to trigger apoptosis
UNKNOWNPhase 2Gastric Neuroendocrine CarcinomaJan 2029
Zhejiang Raygene Pharmaceuticalstirapazamine
Bioreductive hypoxic cytotoxin
UNKNOWNPhase 2HCCApr 2029
Memorial Sloan Kettering Cancer CenterCord Blood Units (HPC(CB))
Allogeneic cord blood hematopoietic progenitor cell transplantation
UNKNOWNPhase 2Acute Myelogenous LeukemiaApr 2030
Patrick Wagner, MD, FACSMitomycin C (HIPEC)
Alkylating agent - DNA crosslinking
UNKNOWNPhase 2Peritoneal (Metastatic) CancerDec 2035
Universiti Sains MalaysiaBifidobacterium longum subsp. infantis M-63, B. breve M-16V, and B. longum BB536
Live Bifidobacterium species (probiotics) to maintain gut microbial balance
UNKNOWNPhase 2Healthy Adults; Healthy Adult Volunteer–
Hayder Adnan FawziMetronidazoleUNKNOWNPhase 2Cutaneous Leishmaniasis–
University Hospital, MontpellierOxaliplatin
Platinum-based alkylating agent; cross-links DNA
UNKNOWNPhase 2Cholangiocarcinoma Non-resectable–
National Cancer Institute (NCI)Radium-223
Alpha particle-emitting radiotherapeutic for skeletal metastases
UNKNOWNPhase 2Biochemical Recurrent Prostate Cancer–
National Institute of Allergy and Infectious Diseases (NIAID)3BNC117-LS
HIV broadly neutralizing antibody
UNKNOWNPhase 1HIV-1Mar 2027
Roswell Park Cancer InstituteMelphalan Hydrochloride
Alkylating agent; DNA crosslinking chemotherapy used in myeloablative conditioning
UNKNOWNPhase 1Acute Myeloid Leukemia in RemissionMay 2027
University of VirginiaRifampin
Bacterial DNA-directed RNA polymerase inhibitor
UNKNOWNPhase 1TuberculosisDec 2027
H. Lee Moffitt Cancer Center and Research InstituteMitomycin C (MMC)
Antineoplastic alkylating agent delivered intraperitoneally as aerosol
UNKNOWNPhase 1Peritoneal CarcinomatosisMar 2028
General OncologyMelphalan
Alkylating agent (nitrogen mustard derivative)
UNKNOWNPhase 1Pancreatic Adenocarcinoma Metastatic; Retinoblastoma; Primary Immunodeficiency (PID); Refractory and/or Relapsed Metastatic Solid Tumors …Dec 2028
The Aurum Institute NPCIsoniazid
Enoyl-[acyl-carrier-protein] reductase inhibitor
UNKNOWNPhase 1HIV Seropositivity–
Iterum Therapeutics, InternationalSulopenem
Bacterial penicillin-binding protein inhibitor
UNKNOWNPhase 1Pharmacokinetics After Oral Intake–

Conditions

HIV-1-infection (10) Pre-Exposure Prophylaxis of HIV Infection (7) Pneumococcal Vaccines (5) HIV Seropositivity (4) Obstructive Sleep Apnea (4) HIV-1 Infection (3) Pyelonephritis Acute (3) Pancreatic Cancer (2) Peritoneal (Metastatic) Cancer (2) Multiple Myeloma (2) HIV Pre-exposure Prophylaxis (2) Peritoneal Metastases (2)

Modalities

small molecule (46), mixed (3), protein or peptide (3), antibody (1)

Companies

Assistance Publique - Hôpitaux de Paris (3) University Hospital, Tours (2) The Aurum Institute NPC (2) Vanderbilt University Medical Center (2) Medicines Development for Global Health (2) Fudan University (1) Theis S. Itenov (1) Pirogov Russian National Research Medical University (1) Wroclaw Medical University (1) Roswell Park Cancer Institute (1) Universiti Sains Malaysia (1) University of Alberta (1) St. Joseph's Hospital and Medical Center, Phoenix (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) Patrick Wagner, MD, FACS (1) General Oncology (1) Monash University (1) Gilead Sciences (1) The University of Hong Kong (1) Cairo University (1)

Related targets

HTR2A (2) CA (1) CPSF6 (1) GAG (1) PROT (1) CAPSID (1) RIPA (1) INH (1) SLC5A2 (1) SLC6A2 (1) GLP1R (1) Tubulin (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.